Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage

被引:57
作者
Dhillon, Harsharan [1 ]
Chikara, Shireen [1 ]
Reindl, Katie M. [1 ]
机构
[1] North Dakota State Univ, Dept Biol Sci, 1340 Bolley Dr,Stevens Hall 201, Fargo, ND 58105 USA
关键词
ROS; Pancreatic cancer; Natural products;
D O I
10.1016/j.toxrep.2014.05.011
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Pancreatic cancer is one of the most deadly cancers with a nearly 95% mortality rate. The poor response of pancreatic cancer to currently available therapies and the extremely low survival rate of pancreatic cancer patients point to a critical need for alternative therapeutic strategies. The use of reactive oxygen species (ROS)-inducing agents has emerged as an innovative and effective strategy to treat various cancers. In this study, we investigated the potential of a known ROS inducer, piperlongumine (PPLGM), a bioactive agent found in long peppers, to induce pancreatic cancer cell death in cell culture and animal models. We found that PPLGM inhibited the growth of pancreatic cancer cell cultures by elevating ROS levels and causing DNA damage. PPLGM-induced DNA damage and pancreatic cancer cell death was reversed by treating the cells with an exogenous antioxidant. Similar to the in vitro studies, PPLGM caused a reduction in tumor growth in a xenograft mouse model of human pancreatic cancer. Tumors from the PPLGM-treated animals showed decreased Ki-67 and increased 8-OHdG expression, suggesting PPLGM inhibited tumor cell proliferation and enhanced oxidative stress. Taken together, our results show that PPLGM is an effective inhibitor for in vitro and in vivo growth of pancreatic cancer cells, and that it works through a ROS-mediated DNA damage pathway. These findings suggest that PPLGM has the potential to be used for treatment of pancreatic cancer. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 24 条
[1]   A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer [J].
Cohen, Steven J. ;
Zalupski, Mark M. ;
Modiano, Manuel R. ;
Conkling, Paul ;
Patt, Yehuda Z. ;
Davis, Peg ;
Dorr, Robert T. ;
Boytim, Michelle L. ;
Hersh, Evan M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) :287-294
[2]  
Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
[3]  
Dorr RT, 2005, J GASTROINTEST CANC, V36, P15, DOI 10.1385/IJGC:36:1:015
[4]   Reactive oxygen species: A breath of life or death? [J].
Fruehauf, John P. ;
Meyskens, Frank L., Jr. .
CLINICAL CANCER RESEARCH, 2007, 13 (03) :789-794
[5]   Perioperative management of pancreatic cancer [J].
Heinemann, V. ;
Boeck, S. .
ANNALS OF ONCOLOGY, 2008, 19 :273-278
[6]   Alleviation of oxidative damage in multiple tissues in rats with streptozotocin-induced diabetes by rice bran oil supplementation [J].
Hsieh, RH ;
Lien, LM ;
Lin, SH ;
Chen, CW ;
Cheng, HJ ;
Cheng, HH .
ROLE OF THE MITOCHONDRIA IN HUMAN AGING AND DISEASE: FROM GENES TO CELL SIGNALING, 2005, 1042 :365-371
[7]   Inhibition of NFκB and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation [J].
Jutooru, Indira ;
Chadalapaka, Gayathri ;
Lei, Ping ;
Safe, Stephen .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (33) :25332-25344
[8]   Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy [J].
Kim, Seung Tae ;
Lim, Do Hyoung ;
Jang, Kee-Taek ;
Lim, Taekyu ;
Lee, Jeeyun ;
Choi, Yoon-La ;
Jang, Hye-Lim ;
Yi, Jun Ho ;
Baek, Kyung Kee ;
Park, Se Hoon ;
Park, Young Suk ;
Lim, Ho Yeong ;
Kang, Won Ki ;
Park, Joon Oh .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (10) :1993-1999
[9]   Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy [J].
Li, Long Shan ;
Bey, Erik A. ;
Dong, Ying ;
Meng, Jieru ;
Patra, Biswanath ;
Yan, Jingsheng ;
Xie, Xian-Jin ;
Brekken, Rolf A. ;
Barnett, Carlton C. ;
Bornmann, William G. ;
Gao, Jinming ;
Boothman, David A. .
CLINICAL CANCER RESEARCH, 2011, 17 (02) :275-285
[10]   KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].
Massarelli, Erminia ;
Varella-Garcia, Marileila ;
Tang, Ximing ;
Xavier, Ana C. ;
Ozburn, Natalie C. ;
Liu, Diane D. ;
Bekele, Benjamin N. ;
Herbst, Roy S. ;
Wistuba, Ignacio I. .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2890-2896